Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance.
Obesity and related metabolic disorders are important side effects of some antipsychotic drugs (APs). The currently available animal model of AP-induced bodyweight gain (BWG) in rats is based on administration of sulpiride (SUL). However, this model has important limitations. For example, SUL is a pure dopamine antagonist, whereas most APs in current clinical use interact with multiple neurotransmitter receptors involved in food intake (FI) and metabolism regulation. Therefore, we evaluated the effects of risperidone (RIS, 0.125, 0.25 or 0.5 mg/kg during 16 days) on BWG and FI in male and female rats. Comparison between RIS (0.5 mg/kg), SUL (20 mg/kg) and vehicle (VEH) during 12 days was also conducted in females. In male rats, RIS did not significantly affect BWG, FI, glucose tolerance or leptin levels, even though prolactin and corticosterone were significantly elevated. In females, both APs significantly increased BWG and FI, but the effect was stronger with SUL. The BWG was significantly associated with an increase in body fat. Serum leptin levels were increased only in SUL-treated rats. The area under the curve for glucose (AUGC) was significantly lower in the SUL group, but it was similar for insulin in all treatment groups. The area under the curve for insulin (AUIC) and BWG positively correlated only in the RIS group. Prolactin and corticosterone were significantly increased by both APs. Serum estradiol levels were significantly increased by RIS but not by SUL, but progesterone levels were similar in both groups. The observed positive correlation between BWG and the AUIC during RIS administration suggests that this agent may represent a better model of AP administration in humans. The animal model of RIS-induced obesity in rats might be improved by testing other doses, route of administration and type of diet.
Baptista
Trino
T
Department of Physiology, Los Andes University Medical School, 5101-A, Mèrida, Venezuela. trinbap@yahoo.com
Araujo de Baptista
Emma
E
Ying Kin
N M K Ng
NM
Beaulieu
Serge
S
Walker
Dominique
D
Joober
Rhida
R
Lalonde
Josee
J
Richard
Denis
D
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001786:Blood Glucose / Q000187:drug effects*; D001823:Body Composition / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D003345:Corticosterone / Q000097:blood; D004435:Eating / Q000187:drug effects*; D004958:Estradiol / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D006728:Hormones / Q000097:blood*; D008297:Male; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D011863:Radioimmunoassay; D051381:Rats; D017208:Rats, Wistar; D018967:Risperidone / Q000494:pharmacology*; D012727:Sex Characteristics; D013469:Sulpiride / Q000494:pharmacology*; D013997:Time Factors
D014150:Antipsychotic Agents; D001786:Blood Glucose; D006728:Hormones; D011374:Progesterone; D004958:Estradiol; D013469:Sulpiride; D011388:Prolactin; D018967:Risperidone; D003345:Corticosterone